logo
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

CNBC16-07-2025
Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, it's from China.
An experimental weekly injection developed by Chinese drugmaker Hengrui Pharma and its U.S.-based partner, Kailera Therapeutics, succeeded in a late-stage trial in China, putting the drugmakers on track to seek approval there.
Kailera is among several companies, such as Merck, Novo Nordisk and Regeneron, that have tapped the Chinese market in search of a drug that could win a slice of the booming weight loss drug market. In May 2024, Kailera licensed rights outside of the Greater China region to multiple experimental drugs from Hengrui in return for more than $100 million in upfront and near-term payments, a 20% equity stake and nearly $6 billion in future milestones.
Here's how the drug, dubbed HRS9531, performed in the trial: It helped patients lose nearly 18% of their body weight on average after 48 weeks, which is more than 16% greater weight loss than those on a placebo saw.
Almost 9 in 10 people who received the injection lost at least 5% of their body weight, and 44.4% of patients achieved at least 20% weight loss, according to a release from the companies. There was no plateau in weight loss at 48 weeks.
The companies didn't disclose specific safety data or how well patients tolerated the drug, only saying those results were consistent with previous data on the treatment and other GLP-1s. Most adverse events from the injection were gastrointestinal-related and mild to moderate in severity, the companies said.
Hengrui will file an approval application for the drug in China. Meanwhile, Kailera will start global studies that use higher doses and keep patients on the treatment for longer, the startup's CEO Ron Renaud said in the release.
It will likely still take several years before HRS9531 enters the market, particularly in the U.S. and other nations outside of China. But the drug's results appear to be promising, and position it as a potential competitor to Eli Lilly's weekly weight loss injection Zepbound.
Both drugs work by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP. The combination is said to slow the emptying of the stomach, making people feel full for longer and suppressing appetite by slowing hunger signals in the brain.
Across two phase three trials enrolling roughly 3,000 adults with obesity or Type 2 diabetes, Zepbound helped patients lose an average of up to 21% of their body weight over 72 weeks.
It's difficult to directly compare results from different clinical trials, especially since the latest results on HRS9531 were only from more than 500 patients. But the drug still achieved significant weight loss over 48 weeks, raising hopes about its potential over a longer period of time.
Meanwhile, Novo Nordisk's weekly injection Wegovy only targets GLP-1.
Feel free to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
Well folks, after a long saga, Anne Wojcicki has officially regained control of the embattled genetic testing company 23andMe.
Wojcicki co-founded 23andMe and served as CEO until the company filed for Chapter 11 bankruptcy protection in March. Her new nonprofit, TTAM Research Institute, has completed its acquisition of the Personal Genome Service and Research Services business lines of 23andMe, the company announced on Monday.
"As part of TTAM, 23andMe is continuing to operate and provide customers with personalized DNA testing and research services," the company said in a release. "TTAM is committed to providing customers with choice and transparency with their data, including the option to change their decision on whether to participate in research."
TTAM is an acronym for the first letters of 23andMe, according to The Wall Street Journal.
23andMe rocketed into the mainstream with at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. But the five-time CNBC Disruptor 50 company struggled to generate recurring revenue and stand up viable research and therapeutics businesses after going public.
When it became clear that 23andMe's financials were shaky, Wojcicki submitted several proposals to take the company private while she was still its chief executive. Those plans were unsuccessful, and she ultimately had to compete against other prospective buyers in a bankruptcy auction.
And, of course, there were some unexpected twists.
In May, Regeneron Pharmaceuticals announced it would purchase most of 23andMe's assets for $256 million after it came out on top during the bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed to reopen the auction.
A month later, she did just that, and TTAM announced that it had successfully outbid Regeneron.
"I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a June statement.
Feel free to send any tips, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Unite Us Offers Proven Path for States to Accelerate Innovation Through H.R. 1 $50B Rural Health Fund
Unite Us Offers Proven Path for States to Accelerate Innovation Through H.R. 1 $50B Rural Health Fund

Business Wire

time23 minutes ago

  • Business Wire

Unite Us Offers Proven Path for States to Accelerate Innovation Through H.R. 1 $50B Rural Health Fund

NEW YORK--(BUSINESS WIRE)--With the recent passage of H.R. 1, the 'One Big Beautiful Bill Act,' states are preparing to operate in new ways, with an eye on leveraging technology to advance access, coordination, and new partnerships to improve how they deliver better care for their populations. 'States are entering a new era of healthcare, with a clear mandate to innovate, increase efficiency, and drive results, and the Rural Health Transformation Program is a critical resource," said Taylor Justice, Co-founder and President of Unite Us. A substantial, but time-sensitive, opportunity for states is the Rural Health Transformation Program (RHTP). This $50 billion fund is designed to support rural healthcare delivery, specifically innovating more efficient and resilient systems. Applications are due by the end of 2025. As states adapt to the new healthcare landscape, the need for proven, data-driven models is paramount. States like Nebraska, Virginia, and North Carolina offer blueprints for success. These states have built a robust, statewide infrastructure, powered by Unite Us, that supports rural communities, enhances access to care, and proves resilient even in the face of natural disasters. This infrastructure has helped tens of thousands across mostly rural regions of the state. In North Carolina alone, the state's ability to coordinate both health and human services in real-time, track outcomes, and manage reimbursements through a single infrastructure has yielded remarkable, and validated, results: Significant Cost Savings: A peer-reviewed study of this coordinated care model shows the state saves an estimated $1,020 per patient per year ($85 PMPM) by addressing barriers and needs like food and housing security. The platform has also enabled an exceptionally low claims denial rate under 2%, far below the healthcare industry average of 15-18%, ensuring community-based organizations are reimbursed for their vital services. 'States are entering a new era of healthcare, with a clear mandate to innovate, increase efficiency, and drive results,' said Taylor Justice, Co-founder and President of Unite Us. 'The Rural Health Transformation Program is a critical resource, and that funding must be deployed with proven strategies to have a lasting impact. Our work in states across the country demonstrates that investing in coordinated care infrastructure is the most effective way to improve health outcomes and generate sustainable savings. We are ready to help states build their plans to ensure this crucial funding is put to its best possible use.' The RHTP is the fastest-moving component of the bill's healthcare provisions. Technological solutions like the Unite Us platform provide states with a turnkey approach to rapidly assemble applications that meet federal requirements, drive efficiency, and deliver meaningful support to underserved rural communities. Unite Us offers state and local governments the digital infrastructure needed to comply with new federal mandates and assist at-risk populations through verification assistance for eligibility redetermination, closed-loop referrals to both existing health and employment community resources, integrated reporting and analytics, and streamlined payments management. All non-profit community-based organizations can use Unite Us' platform free of charge. Contact us to learn more: About Unite Us Founded in 2013 by Military Veterans, Unite Us is the nation's premier technology provider for integrating health and community-based care. Our advanced product suite is used to proactively coordinate services using data-driven insights, streamline referral and case management, and facilitate eligibility assessments and reimbursements across government, healthcare, health plans, and community organizations. The first of its kind, our closed-loop referral system prioritizes privacy and dignity and has integrated data and analytics tools used to measure impact, optimize programs, and shape policy. With over 1.7M services, we host the nation's largest network of community-based health and economic services dedicated to improving whole-person health. Learn more at and LinkedIn.

US and China to talk in Stockholm as trade truce expiration nears
US and China to talk in Stockholm as trade truce expiration nears

Yahoo

time41 minutes ago

  • Yahoo

US and China to talk in Stockholm as trade truce expiration nears

When top US and Chinese officials meet in Stockholm on Monday, it's likely that they will agree to leave tariffs at the current levels, if they don't secure a more favourable framework. Analysts say the two sides are working to secure a more lasting trade deal ahead of a meeting between their presidents later this year. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng are holding talks on Monday for the third time this year. This round of discussions is taking place in the Swedish capital, nearly four months after President Donald Trump upset global trade with his sweeping tariff proposal, including an import tax that shot up to 145% on Chinese goods. 'We have the confines of a deal with China,' Trump said on Friday. Bessent told MSNBC on Wednesday that the two countries had reached a 'status quo' after talks in Geneva and London, with the US taxing imported goods from China at 30% and China responding with a 10% tariff, on top of tariffs prior to the start of Trump's second term in office. 'Now we can move on to discussing other matters in terms of bringing the economic relationship into balance,' Bessent said. He was referring to the US running a $295.5 billion (€253.1bn) trade deficit last year. Washington is seeking an agreement that would enable it to export more to China and shift the Chinese economy more toward domestic consumer spending. The Chinese embassy in Washington said Beijing hopes 'there will be more consensus and cooperation and less misperception' coming out of the talks. With an eye on a possible leaders' summit, Stockholm could provide some answers as to the timeline and viability of that particular goal ahead of a possible meeting between Trump and Chinese leader Xi Jinping. 'The meeting will be important in starting to set the stage for a fall meeting between Trump and Xi,' said Wendy Cutler, a former US trade negotiator and now vice president at the Asia Society Policy Institute. 'Beijing will likely insist on detailed preparations before they agree to a leaders' meeting.' In Stockholm, the two sides are likely to focus on commercial announcements to be made at a leaders' summit as well as agreements to address 'major irritants', such as China's industrial overcapacity and its lack of control over chemicals used to make fentanyl, also to be announced when Xi and Trump should meet, Cutler said. Sean Stein, president of the US-China Business Council, said Stockholm could be the first real opportunity for the two governments to address structural reform issues including market access in China for US companies. What businesses will be seeking coming out of Stockholm would largely be 'the atmosphere' — how the two sides characterise the discussions. They will also look for clues about a possible leaders' summit, as any real deal will hinge on the two presidents meeting each other, he said. Fentanyl-related tariffs are likely a focus for China In Stockholm, Beijing will likely demand the removal of the 20% fentanyl-related tariff that Trump imposed earlier this year, said Sun Yun, director of the China program at the Washington-based Stimson Center. This round of the US-China trade dispute began with fentanyl, when Trump in February imposed a 10% tariff on Chinese goods, citing that China failed to curb the outflow of the chemicals used to make the drug. The following month, Trump added another 10% tax for the same reason. Beijing retaliated with extra duties on some US goods, including coal, liquefied natural gas, and farm products such as beef, chicken, pork and soy. In Geneva, both sides climbed down from three-digit tariffs rolled out following Trump's 'Liberation Day' tariffs in April, but the US kept the 20% 'fentanyl' tariffs, in addition to the 10% baseline rate — to which China responded by keeping the same 10% rate on US products. These across-the-board duties were unchanged when the two sides met in London a month later to negotiate over non-tariff measures such as export controls on critical products. Related Beijing confirms that it has signed a trade agreement with the US Volvo Cars CEO: dual tech for China and the West is new trade reality The Chinese government has long protested that American politicians blame China for the fentanyl crisis in the US but argued the root problem lies with the US itself. Washington says Beijing is not doing enough to regulate precursor chemicals that flow out of China into the hands of drug dealers. In July, China placed two fentanyl ingredients under enhanced control, a move seen as in response to US pressure and signalling goodwill. Gabriel Wildau, managing director at the consultancy Teneo, said he doesn't expect any tariff to go away in Stockholm but that tariff relief could be part of a final trade deal. 'It's possible that Trump would cancel the 20% tariff that he has explicitly linked with fentanyl, but I would expect the final tariff level on China to be at least as high as the 15-20% rate contained in the recent deals with Japan, Indonesia, Vietnam,' Wildau said. US wants China to dump less, buy less oil from Russia and Iran China's industrial overcapacity is as much a headache for the United States as it is for the European Union. Even Beijing has acknowledged the problem but suggested it might be difficult to address. America's trade imbalance with China has decreased from a peak of $418bn (€358bn) in 2018, according to the Census Bureau. But China has found new markets for its goods; the world's dominant manufacturer ran a global trade surplus approaching $1 trillion last year — somewhat larger than the size of the US overall trade deficit in 2024. And China's emergence as a manufacturer of electric vehicles and other emerging technologies has suddenly made it more of a financial and geopolitical threat for those same industries based in the US, Europe, Japan and South Korea. 'Some enterprises, especially manufacturing enterprises, feel more deeply that China's manufacturing capabilities are too strong, and Chinese people are too hardworking. Factories run 24 hours a day,' Chinese Premier Li Qiang said on Thursday when hosting European Commission President Ursula von der Leyen in Beijing. 'Some people think this will cause some new problems in the balance of supply and demand in world production.' Li added: 'We see this problem too.' Bessent also said the Stockholm talks could address Chinese purchases of Russian and Iranian oil. However, Wildau of Teneo said China could demand some US security concessions in exchange, such as a reduced US military presence in East Asia and scaled-back diplomatic support for Taiwan and the Philippines. This would likely face political pushback in Washington. The Stockholm talks will be 'geared towards building a trade agreement based around Chinese purchase commitments and pledges of investment in the US in exchange for partial relief from U.S. tariffs and export controls,' Wildau said. He doubts there will be a grand deal. Instead, he predicts 'a more limited agreement based around fentanyl'. 'That,' he said, 'is probably the preferred outcome for China hawks in the Trump administration, who worry that an overeager Trump might offer too much to Xi.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oil Prices Up 2.5% As OPEC+ Agrees To Maintain Production Levels
Oil Prices Up 2.5% As OPEC+ Agrees To Maintain Production Levels

Yahoo

time44 minutes ago

  • Yahoo

Oil Prices Up 2.5% As OPEC+ Agrees To Maintain Production Levels

OPEC+ stuck to the script at Monday's Joint Ministerial Monitoring Committee (JMMC) meeting, offering no changes to current output policy and little surprise for market watchers. The virtual meeting—its 61st—reviewed production data from May and June and confirmed what most already suspected: while the group remains on track with its broad plans, not every member is keeping pace. The committee emphasized once again the 'critical importance' of full conformity with the agreed production levels, especially in light of the phased unwinding of 2.2 million bpd in voluntary cuts that began earlier this year. Countries that underdelivered on those pledges have until August 18 to submit updated compensation plans—essentially, promises to make up for past shortfalls. The JMMC also reiterated its role in monitoring output targets set at the 38th OPEC and non-OPEC Ministerial Meeting last December and the voluntary adjustments announced in February. Importantly, the committee stressed—again—that it doesn't actually make production decisions, a clarification aimed at tempering market expectations ahead of each meeting. The 548,000 bpd production increase scheduled for August still appears on track, though execution remains uneven. As noted ahead of the meeting, not all members have delivered their share of the increases to date, which has muted the market impact of these headline figures. OPEC's latest internal outlook shows steady demand through the second half of 2025 but warns of persistent risks—soft macro data, weaker-than-hoped Chinese momentum, and rising EV penetration, among others. So far, the strategy appears to be steady as she goes. The next JMMC meeting is set for October 1. Until then, traders will be watching for more signs of whether the promised barrels actually show up—or whether compliance issues will force another recalibration. By Julianne Geiger for More Top Reads From this article on Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store